Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer’s Disease
Molecular Neurobiology, ISSN: 1559-1182, Vol: 59, Issue: 10, Page: 6107-6124
2022
- 18Citations
- 28Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations18
- Citation Indexes18
- 18
- Captures28
- Readers28
- 28
- Mentions1
- News Mentions1
- News1
Most Recent News
Dysregulated miRNAs in Progression and Pathogenesis of Alzheimer's Disease.
Mol Neurobiol. 2022 Jul 22; Authors: Arora T, Prashar V, Singh R, Barwal TS, Changotra H, Sharma A, Parkash J PubMed: 35867206 Submit Comment
Review Description
Alzheimer’s disease (AD) is a progressive degeneration of neurons due to the accumulation of amyloid-β peptide (Aβ) and hyper-phosphorylation of tau protein in the neuronal milieu leading to increased oxidative stress and apoptosis. Numerous factors contribute towards the progression of AD, including miRNA, which are 22–24 nucleotides long sequence which acts as critical regulators of cellular processes by binding to 3′ UTR of mRNA, regulating its expression post-transcriptionally. This review aims to determine the miRNA with the most significant dysregulation in the brain and cerebrospinal fluid (CSF) of human patients. A systemized inclusion/exclusion criterion has been utilized based on selected keywords followed by screening of those articles to conclude a list of 8 highly dysregulated miRNAs based on the fold change of AD vs control patients, which could be used in clinical testing as these miRNAs play central role in the pathophysiology of AD. Furthermore, a network study of highly dysregulated miRNA estimated the association of these miRNA in the mediation of Aβ generation and aggregation, inhibition of autophagy, reduction of Aβ clearance, microglial and astrocytic activation, neuro-inflammation, tau hyper-phosphorylation, and synaptic loss.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85134659721&origin=inward; http://dx.doi.org/10.1007/s12035-022-02950-z; http://www.ncbi.nlm.nih.gov/pubmed/35867206; https://link.springer.com/10.1007/s12035-022-02950-z; https://dx.doi.org/10.1007/s12035-022-02950-z; https://link.springer.com/article/10.1007/s12035-022-02950-z
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know